Le Lézard
Classified in: Health, Business
Subject: TNM

Avara Pharmaceutical Services acquires secondary solid dosage form manufacturing, packaging and distribution facility from AstraZeneca in France



NORWALK, Conn., Oct. 6, 2017 /PRNewswire/ -- Avara Pharmaceutical Services has signed and closed on an agreement with AstraZeneca to acquire the Reims, France manufacturing and distribution facility. "This key acquisition is another important component of our strategic plan that further expands our services," stated Timothy C. Tyson, Chairman and CEO.

Tim Tyson, a global leader in the pharmaceutical industry, is Chairman and CEO of Avara Pharmaceutical Services. In his 35-plus year career, Mr. Tyson has negotiated complex multi-billion dollar mergers and acquisitions, led major turn-arounds that have fueled growth and value and, most significantly, has been instrumental in bringing more than 50 lifesaving and life improving medicines to the market.

Avara Pharmaceutical Services is a state-of-the-art contract manufacturing and technical services organization providing both API formulation and manufacturing, along with secondary formulation, manufacturing, packaging and distribution of small molecule drugs, including highly potent compounds. Avara has secondary manufacturing technologies including granulation, coating, blending, encapsulation, compression and drying of tablets and capsules. Avara also has secondary sterile manufacturing capability in the Liscate site.

Welcoming the Reims team to Avara Pharmaceutical Services, the company now has eight sites: three in the US, including the corporate HQ's; one in Puerto Rico; one in the UK; one in Ireland; one in Italy and this new additional site in France.

1. Norwalk, CT (USA) - Corporate HQ 2. Arecibo, Puerto Rico -Development, Secondary manufacturing and packaging 3. Shannon, Ireland - Development and API formulation and manufacturing 4. Norman, OK (USA) -Development and Secondary manufacturing and packaging 5. Avlon, United Kingdom ?Development and API formulation and manufacturing 6. Liscate, Italy-Development and Sterile Manufacturing 7. Aiken, South Carolina?Secondary manufacturing and packaging 8. Reims, France ? Development and Secondary manufacturing, packaging and distribution

"With rapid expansion and integration set for 2017-2018, we continue, with great confidence, to build a pharmaceutical services company with complementary offerings in key regions to serve the rapidly growing market. Each site has significant professional experience, state of the art capability and a long history of delivering high quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements in every major market around the world. The people who are a part of the Avara team are the key to our long-term success," said Tyson.

About Avara

Avara Pharmaceutical Services, Inc., based in Norwalk, Connecticut is an international pharmaceutical services company that delivers world-class contract manufacturing and technical services to the pharmaceutical industry. Avara has development and primary and secondary manufacturing facilities in North America and Europe and supplies products to all major markets around the world. Avara's broad experience with supply chain, commercialization, product launch and product transfer allows us to sustain exemplary levels of product quality and regulatory compliance. The company is known to exceed customer service level expectations and consistently deliver on time, in full at a fair price. For more information, please visit our website at www.avara.com.

Contact: Guy Tiene, guy@thatsnice.com

Avara Pharmaceutical Services, Inc. (PRNewsfoto/Avara Pharmaceutical Services,)

SOURCE Avara Pharmaceutical Services, Inc.


These press releases may also interest you

at 17:00
Open Access publishing is gaining popularity as the world is increasingly connected online today, facilitating archiving, indexing, data mining, retrieving, and speedy distribution of researched information. Open access publishing is producing a...

at 17:00
Renovatm Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that an abstract of a study in a preclinical model of type 1 diabetes was accepted as a...

at 16:00
People with type 1 diabetes (T1D) who take 200 mg or 400 mg of sotagliflozin in addition to optimized insulin therapy have statistically lower HbA1c levels and weight, as well as low incidence of severe hypoglycemia after a year of treatment,...

at 16:00
ORLANDO, Fla., June 24, 2018 /PRNewswire-USNewswire/ -- Adding the selective SGLT2 inhibitor dapagliflozin to intensive insulin therapy in adults with type 1 diabetes (T1D) who had sub-optimal glycemic control reduced blood glucose levels, aided in...

at 12:00
The Honourable Ginette Petitpas Taylor, Minister of Health, and the Honourable Brian Gallant, Premier of New Brunswick, will announce the launch of the Healthy Seniors Pilot Project, on behalf of the Government of Canada and the Government of New...

at 11:00
GLEN ROCK, N.J., June 24, 2018 /PRNewswire-PRWeb/ -- Orthopaedic surgeon, Dr. Deepan Patel, of Sovereign Health System is one of few physician's in the area to use the award winning Lipogems device that gently processes and uses your body's own fat...




News published on 6 october 2017 at 12:12 and distributed by: